Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Combined Inhibition of HRAS and MEK Induces Tumor Regression and Restores Myogenic Differentiation in HRAS-Mutant Rhabdomyosarcoma.

Cancer research - 15 May 2026

Odeniyide Patience, Skaist Alyza, Fenner Elizabeth, Amirkhanian Hanah, Baker Andrew, Lisok Alla, Zhang Lindy, Fridman Lisa B, Rojas Rafael I, Hebron Katie E, Davis Christopher, Zhang Xiaohu, Feldman Gabrielle, Angus Steven P, Thomas Craig J, Vaseva Angelina V, Yohe Marielle E, Fertig Elana J, Pratilas Christine A

Abstract excerpt

Hyperactive RAS signaling, induced by mutations in NRAS, HRAS, or KRAS, drives tumorigenesis in most PAX3/7::FOXO1 fusion-negative rhabdomyosarcomas (FN-RMS). Despite the frequency of these mutations, indirect RAS pathway-directed therapies have been ineffective for RAS-driven RMS. Farnesyltransferase (FTase) inhibitors (FTI), such as tipifarnib, inhibit HRAS membrane localization and blunt RAS effector...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Differentiation
Share to Farnesyltranstransferase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Muscle Development

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins p21(ras)

Share to Quinolones

Share to Rhabdomyosarcoma

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 41671396
DOI: 10.1158/0008-5472.CAN-25-2985
PMCID: PMC13176821

Genes

HRAS
FOXO1
KRAS
NRAS
PAX3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Combined Inhibition of HRAS and MEK Induces Tumor Regression and Restores Myogenic Differentiation in HRAS-Mutant Rhabdomyosarcoma.PMID 41671396Read ↗

Targeting farnesylation as a novel therapeutic approach in HRAS-mutant rhabdomyosarcomaSemantic proximity Read ↗

Therapeutic targeting of ATR in alveolar rhabdomyosarcomaSemantic proximity Read ↗

Single-cell profiling of alveolar rhabdomyosarcoma reveals RAS pathway inhibitors as cell-fate hijackers with therapeutic relevanceSemantic proximity Read ↗

Sensitization to Ionizing Radiation by MEK inhibition is Dependent on SNAI2 in Fusion-negative RhabdomyosarcomaSemantic proximity Read ↗

Role of Myc family proteins in transcriptional regulation of growth and oncogenic transformation in fusion-positive rhabdomyosarcomaSemantic proximity Read ↗

NRAS-Mutated Rhabdomyosarcoma Cells Are Vulnerable to Mitochondrial Apoptosis Induced by Coinhibition of MEK and PI3Kα.Semantic proximity Read ↗

Probing for a deeper understanding of rhabdomyosarcoma: insights from complementary model systems.Semantic proximity Read ↗

Genomic and Epigenetic Changes Drive Aberrant Skeletal Muscle Differentiation in RhabdomyosarcomaSemantic proximity Read ↗

RAS isoform specific activities are disrupted by disease associated mutations during cell differentiationSemantic proximity Read ↗

HER Tyrosine Kinase Family and Rhabdomyosarcoma: Role in Onset and Targeted TherapySemantic proximity Read ↗

Tipifarnib Inhibits HRAS-Driven Dedifferentiated Thyroid Cancers.Semantic proximity Read ↗

Exploiting a PAX3-FOXO1-induced synthetic lethal ATR dependency for rhabdomyosarcoma therapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.